title: Autologous hematopoietic stem cell transplantation as a treatment option for aggressive multiple sclerosis.
abstract: Despite the development of several injectable or oral treatments for relapsing-remitting multiple sclerosis (RRMS), it remains difficult to treat patients with aggressive disease, and many of these continue to develop severe disability. During the last two decades autologous hematopoietic stem cell transplantation (aHSCT) has been explored with the goal to eliminate an aberrant immune system and then re-install a healthy and tolerant one from hematopoietic precursor cells that had been harvested from the patient prior to chemotherapy. Clinical studies have shown that aHSCT is able to completely halt disease activity in the majority of patients with aggressive RRMS. Research on the mechanisms of action supports that aHSCT indeed leads to renewal of a healthy immune system. Below we will summarize important aspects of aHSCT and mention the currently best-examined regimen.
authors: Neuroimmunology and MS Research, Department of Neurology, University Hospital Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland.
authors: Nikolai
authors: N
authors: Pfender
authors: Riccardo
authors: R
authors: Saccardi
authors: Roland
authors: R
authors: Martin
references: Eur Neurol. 2008;60(1):1-11
references: 18437041
references: Trends Immunol. 2006 Feb;27(2):61-7
references: 16406806
references: Neurology. 2004 Jan 27;62(2):282-4
references: 14745069
references: J Exp Med. 2005 Mar 7;201(5):805-16
references: 15738052
references: Lancet Neurol. 2009 Mar;8(3):244-53
references: 19186105
references: Brain. 2004 May;127(Pt 5):996-1008
references: 14985264
references: Neurology. 2011 Sep 27;77(13):1246-52
references: 21917763
references: J Immunol. 2003 Jul 1;171(1):432-7
references: 12817027
references: J Neuropathol Exp Neurol. 2007 Jul;66(7):637-49
references: 17620989
references: Lancet. 2000 May 27;355(9218):1875-81
references: 10866444
references: Mult Scler. 2006 Dec;12(6):824-5
references: 17263013
references: Mult Scler. 2012 Jun;18(6):835-42
references: 22127896
references: Lancet. 2009 Oct 31;374(9700):1503-11
references: 19815268
references: Blood. 2011 Aug 11;118(6):1693-8
references: 21596847
references: Haematologica. 2010 Feb;95(2):284-92
references: 19773265
references: Biol Blood Marrow Transplant. 2012 Jan;18(1 Suppl):S177-83
references: 22226104
references: Blood. 2005 Sep 1;106(5):1875-83
references: 15899918
references: Bone Marrow Transplant. 2005 Apr;35(8):737-46
references: 15750612
references: Lancet Neurol. 2008 Mar;7(3):268-77
references: 18275928
references: Mult Scler. 2012 Aug;18(8):1188-92
references: 22252466
references: Haematologica. 2003 Mar;88(3):306-14
references: 12651270
references: J Immunol. 2005 Mar 15;174(6):3158-63
references: 15749843
references: Lancet Neurol. 2009 Nov;8(11):987-97
references: 19748319
references: Lancet Neurol. 2008 Jul;7(7):626-36
references: 18565456
references: Mult Scler. 2012 Jun;18(6):772-5
references: 22619224
references: Mult Scler. 2006 Dec;12(6):814-23
references: 17263012
references: Biol Blood Marrow Transplant. 2010 Aug;16(8):1076-83
references: 20304084
references: Mult Scler. 2012 Jun;18(6):825-34
references: 22383228
references: Bone Marrow Transplant. 2010 Feb;45(2):239-48
references: 19584827
references: Methods Mol Biol. 2009;549:231-46
references: 19378207
references: Curr Opin Neurol. 2012 Jun;25(3):246-51
references: 22547098
references: Blood. 1998 Nov 15;92(10):3505-14
references: 9808541